Is Supernus Pharmaceuticals (SUPN) overvalued or fairly valued?

MarketChacha shows Supernus Pharmaceuticals's valuation in context — a forward P/E of about 10.8, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Supernus Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (9.02×) from reported figures — education, not a rating.

What is Supernus Pharmaceuticals's revenue?

Supernus Pharmaceuticals reported revenue of $719.0M for FY2025, with net profit of $-38.5M, per official filings.

What is the share price of Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals last traded at $47.06 (-1.7% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Supernus Pharmaceuticals

SUPN · NYSE · Healthcare · United States

$47.06-1.7%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:32 PM

Snapshot

TickerSUPN

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees778

HeadquartersRockville, United States

Market cap$2.7B

P/B2.5

Volume198.9K

Websitewww.supernus.com

Filings tracked6

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Profile as reported by Yahoo Finance.

Who owns it

Insiders4.5%
Institutions95.5%
Public & other0.0%

454 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.16%
Millennium Management Llc5.71%
Vanguard Portfolio Management LLC5.58%
Vanguard Capital Management LLC4.25%
Dimensional Fund Advisors LP3.97%
State Street Corporation3.94%
Nomura Asset Management International Inc3.51%
Armistice Capital, LLC3.27%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Cash conversion9.02×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend0.2% → -5.4%

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Return on equity-3.6%

Latest ROE of -3.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $219.0M · EPS 0.66

Est. earnings growth +9.2%

Next fiscal year

Rev $1.0B · EPS 4.34

Est. earnings growth +74.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$32.5152-wk range$59.68

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$2.7B

Day change

-1.7%

Fwd P/E

10.8

P/B

2.5

Beta

0.54

Revenue (FY2025)

$719.0M

Net margin

-5.4%

ROE

-3.6%

Revenue CAGR (2y)

+8.8%

EPS (FY2025)

-0.68

Net profit (FY2025)

$-38.5M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about SUPN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$719.0M	$-38.5M	-0.68	-5.4%	-3.6%
FY2024	$661.8M	$73.9M	1.32	11.2%	7.1%
FY2023	$607.5M	$1.3M	0.02	0.2%	0.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$207.7M	$-2.3M	-0.04	-1.1%
2025Q3	$192.1M	$-45.1M	-0.80	-23.5%
2025Q2	$165.5M	$22.5M	0.40	13.6%
2025Q1	$149.8M	$-11.8M	-0.21	-7.9%
2024Q3	$175.7M	$38.5M	0.69	21.9%
2024Q2	$168.3M	$19.9M	0.36	11.8%
2024Q1	$143.6M	$124,000	0.00	0.1%
2023Q3	$153.9M	$-16.0M	-0.29	-10.4%
2023Q2	$135.6M	$-831,000	-0.02	-0.6%
2023Q1	$153.8M	$16.9M	0.29	11.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Shareholder vote results, Exhibits
SEC6/18/2026material
8-K — Material financial obligation, Exhibits
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations
SEC4/22/2026material
8-K — Material agreement, Completion of acquisition/disposition, Exhibits
SEC4/7/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.